Mumps is Back: Why is Mumps Eradication Not Working?

  • Noni MacDonald
  • Todd Hatchette
  • Lotfia Elkout
  • Shelly Sarwal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 697)

Abstract

Mumps has been recognized as a common childhood illness since the time of Hippocrates in the fifth century BC. In 1790, central nervous system involvement was described by Hamilton and, in 1860, sensorineural deafness by Toynebee.

References

  1. 1.
    Habel K. Vaccination of human beings against mumps; vaccine administered at the start of an epidemic. I. Incidence and severity of mumps in vaccinated and control groups. Am J Hyg. 1951;54(3):295–311.PubMedGoogle Scholar
  2. 2.
    World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51-60.Google Scholar
  3. 3.
    Fullerton KE, Reef SE. Commentary Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control. Int J Epidemiol. 2002;31(5):983–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Health Protection Agency. Continued increase in mumps in universities 2008/2009 News; 2009 April. http://www.hpa.org.uk/hpr/archives/2009/news1409.htm
  5. 5.
    Sartorius B, Penttinen P, Nilsson J, Johansen K, Jonsson K, Arneborn M et al. An outbreak of mumps in Sweden, Feb–Apr 2004. Euro Surveill. 2005;10(9):191–3. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=559.PubMedGoogle Scholar
  6. 6.
    Karagiannis I, van Lier A, van Binnendijk R, Ruijs H, Ruijs H, Fanoy E et al. Mumps in a community with low vaccination coverage in the Netherlands. Euro Surveill. 2008;13(24). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18901.PubMedGoogle Scholar
  7. 7.
    Watson-Creed G, Saunders A, Scott J, Lowe L, Pettipas J, Hatchette TF. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ. 2006;175(5):483–8.PubMedGoogle Scholar
  8. 8.
    Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the “forgotten” age group in the 1998 Australian measles control campaign. Med J Aust. 2008;189(8):434–7.PubMedGoogle Scholar
  9. 9.
    Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358(15):1580–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine. 2004;22(21–22):2713–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis. 2008;8(12):796–803.CrossRefPubMedGoogle Scholar
  12. 12.
    Vandermeulen C, Leroux-Roels G, Hoppenbrouwers K. Mumps outbreaks in highly vaccinated populations: What makes good even better?. Hum Vaccin. 2009;5(7):494–6.PubMedGoogle Scholar
  13. 13.
    Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77(1):3–14.PubMedGoogle Scholar
  14. 14.
    Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371(9616):932–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Agarwal T, Rahman N, Abel R. Down in the mumps. J Pediatr Surg. 2006;41(12):e17–18.CrossRefPubMedGoogle Scholar
  16. 16.
    Hashimoto H, Fujioka M, Kinumaki H. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J. 2009;28(3):173–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Baas MC, van Donselaar KA, Florquin S, van Binnendijk RS, ten Berge IJ, Bemelman FJ. Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant. 2009;9(9):2186–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Plotkin SA, Rubin SA. Mumps vaccine. In: SA Plotkin WA Orenstein, PA Offit editors. Vaccines. 5th ed. Philadelphia, PA: Elsevier; 2008. p. 435–65.Google Scholar
  19. 19.
    Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol. 2006;21(4):446–57.CrossRefPubMedGoogle Scholar
  20. 20.
    Anderson LJ, Seward JF. Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J. 2008;27(10 Suppl):S75–S79.PubMedGoogle Scholar
  21. 21.
    Rubin SA, Amexis G, Pletnikov M, Li Z, Vanderzanden J, Mauldin J et al. . Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol. 2003;77(21):11616–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Rubin SA, Afzal MA, Powell CL, Bentley ML, Auda GR, Taffs RE et al. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis. 2005;191(7):1123–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Johansson B, Tecle T, Orvell C. Proposed criteria for classification of new genotypes of mumps virus. Scand J Infect Dis. 2002;34(5):355–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis. 2008;47(11):1458–67.CrossRefPubMedGoogle Scholar
  25. 25.
    Friedman M, Hadari I, Goldstein V, Sarov I. Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection. Isr J Med Sci. 1983;19(10):881–4.PubMedGoogle Scholar
  26. 26.
    Friedman MG. Radioimmunoassay for the detection of virus-specific IgA antibodies in saliva. J Immunol Methods. 1982;54(2):203–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet. 1952;2(6734):549–54.CrossRefPubMedGoogle Scholar
  28. 28.
    World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases Geneva; 2003. http://www.who.int/immunization_monitoring/diseases/mumps_surveillance/en/
  29. 29.
    Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis. 2005;191(5):719–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Brook I. Diagnosis and management of parotitis. Arch Otolaryngol Head Neck Surg. 1992;118(5):469–71.PubMedGoogle Scholar
  31. 31.
    Bastien N, Bowness D, Burton L, Bontovics E, Winter AL, Tipples G et al. Parotitis in a child infected with triple-reassortant influenza A virus in Canada in 2007. J Clin Microbiol. 2009;47(6):1896–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Falk WA, Buchan K, Dow M, Garson JZ, Hill E, Nosal M et al. The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol. 1989;130(4):736–49.PubMedGoogle Scholar
  33. 33.
    CDC (Atlanta) http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps_2008.htm last accessed 10 Sep, 2009.
  34. 34.
    Leland DS. Parainfluenza and mumps viruses. In: PR Murray, EJ Baron, JH Jorgensen, ML Landry and MA Pfaller (ed.). Manual of Clinical Microbiology. 2007; 9:1352–60; Washington, DC: ASM Press.Google Scholar
  35. 35.
    Krause CH, Eastick K, Ogilvie MM. Real-time PCR for mumps diagnosis on clinical specimens–comparison with results of conventional methods of virus detection and nested PCR. J Clin Virol. 2006;37:184–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Hatchette TF, Davidson R, Clay S, Pettipas J, LeBlanc J, Sarwal S, Smieja M, Forward KR. Laboratory diagnosis of mumps in a partially immunized population: The Nova Scotia Experience. Can J Infect Dis Med Microbiol. 2009;20(4):e157–e162.Google Scholar
  37. 37.
    CDC (Atlanta) http://www.cdc.gov/ncphi/disss/nndss/casedef/mumps_2008.htm last accessed 10 Sep 2009.
  38. 38.
    Germann D, Gorgievski A, Strohle A, Matter L. Detection of mumps virus in clinical specimens by rapid centrifugation culture and conventional tube cell culture. J Virol Methods. 1998;73:59–64.CrossRefPubMedGoogle Scholar
  39. 39.
    Uchida K, Shinohara M, Shimada S, Segawa Y, Doi R, Gotoh A, Hondo R. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol. 2005;75:470–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Jin L, Beard S, Brown DW. Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. J Infect Dis. 1999;180:829–33.CrossRefPubMedGoogle Scholar
  41. 41.
    Boddicker JD, Rota PA, Kreman T, Wangeman A, Lowe L, Hummel KB, Thompson R, Bellini WJ, Pentella M, Desjardin LE. Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol. 2007;45:2902–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Leblanc JJ, Pettipas J, Davidson RJ, Tipples GA, Hiebert J, Hatchette TF. Detection of mumps virus RNA by real-time one-step reverse transcriptase PCR using the LightCycler platform. J Clin Microbiol. 2008;46:4049–51.CrossRefPubMedGoogle Scholar
  43. 43.
    Jin L, Feng Y, Parry R, Cui A, Real-time LuY. PCR and its application to mumps rapid diagnosis. J Med Virol. 2007;79:1761–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Krause CH, Molyneaux PJ, Ho-Yen DO, McIntyre P, Carman WE, Templeton. KE. J Clin Virol. 2007;38:153.CrossRefPubMedGoogle Scholar
  45. 45.
    Rota JS, Turner JC, Yost-Daljev MK, Freeman M, Toney DM, Meisel E, Williams N, Sowers SB, Lowe L, Rota PA, Nicolai LA, Peake L, Bellini WJ. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol. 2009;81:1819–25.CrossRefPubMedGoogle Scholar
  46. 46.
    Pipkin PA, Afzal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus. J Virol Methods. 1999;79:219–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Ballew HC. In: S Specter, RL Hodinka, SA Young editors. Neutralization in: clinical virology manual, 3rd ed. Washington, DC. ASM Press, 2000. p. 127–34.Google Scholar
  48. 48.
    Tipples GA, Beirnes J, Hiebert J, Hatchette T, Pettipas J, Macey J, Deeks S, Lipskie T, Bellini W, Rota P, Rota J Laboratory Guidelines for the diagnosis of mumps v.3 (3 Apr 2008) http://www.nml-lnm.gc.ca/guide/guideview-eng.asp?key=186 (Last accessed 10 Sep 2009:1352–1360).
  49. 49.
    Jick H, Chamberlin DP, Hagberg KW. The origin and spread of a mumps epidemic: United kingdom, 2003–2006. Epidemiology. 2009;20(5):656–61.CrossRefPubMedGoogle Scholar
  50. 50.
    Muhlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol. 2004;4(3):215–19.CrossRefPubMedGoogle Scholar
  51. 51.
    Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine. 2006;24(49–50):7037–45.CrossRefPubMedGoogle Scholar
  52. 52.
    World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51–60.Google Scholar
  53. 53.
    Stokes J Jr, Weibel RE, Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. II. Early clinical studies. Pediatrics. 1967;39(3):363–71.PubMedGoogle Scholar
  54. 54.
    Asatryan A, Pool V, Chen RT, Kohl KS, Davis RL, Iskander JK. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990–2003. Vaccine. 2008;26(9):1166–72.CrossRefPubMedGoogle Scholar
  55. 55.
    Kaic B, Gjenero-Margan I, Aleraj B, Ljubin-Sternak S, Vilibic-Cavlek T, Kilvain S et al. Transmission of the L-Zagreb mumps vaccine virus, Croatia, 2005–2008. Euro Surveill. 2008;13(16). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18843.PubMedGoogle Scholar
  56. 56.
    Tesovic G, Poljak M, Lunar MM, Kocjan BJ, Seme K, Vukic BT et al. Horizontal transmission of the Leningrad-Zagreb mumps vaccine strain: a report of three cases. Vaccine. 2008;26(16):1922–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Atrasheuskaya AV, Neverov AA, Rubin S, Ignatyev GM. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine. 2006;24(10):1530–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Weibel RE, Stokes J Jr, Buynak EB, Whitman JE Jr, Hilleman MR. Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med. 1967;276(5):245–51.CrossRefPubMedGoogle Scholar
  59. 59.
    Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341(8851):979–82.CrossRefPubMedGoogle Scholar
  60. 60.
    LeBaron CW, Forghani B, Beck C, Brown C, Bi D, Cossen C et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;199(4):552–60.CrossRefPubMedGoogle Scholar
  61. 61.
    Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 1995;13(9):799–802.CrossRefPubMedGoogle Scholar
  62. 62.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Jokinen S, Osterlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis. 2007;196(6):861–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine. 2005;23(31):4070–4.CrossRefPubMedGoogle Scholar
  65. 65.
    Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis. 2007;45(4):459–66.CrossRefPubMedGoogle Scholar
  66. 66.
    Beck M, Welsz-Malecek R, Mesko-Prejac M, Radman V, Juzbasic M, Rajninger-Miholic M et al. . Mumps vaccine L-Zagreb, prepared in chick fibroblasts. I. Production and field trials. J Biol Stand. 1989;17(1):85–90.CrossRefPubMedGoogle Scholar
  67. 67.
    Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26(7):632–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Boxall N, Kubinyiova M, Prikazsky V, Benes C, Castkova J. An increase in the number of mumps cases in the Czech Republic, 2005–2006. Euro Surveill. 2008;13(16). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18842.PubMedGoogle Scholar
  69. 69.
    Bernard H, Schwarz NG, Melnic A, Bucov V, Caterinciuc N, Pebody RG et al. . Mumps outbreak ongoing since October 2007 in the Republic of Moldova. Euro Surveill. 2008;13(13). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8079.Google Scholar
  70. 70.
    Kaaijk P, van der Zeijst B, Boog M, Hoitink C. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008;13(26). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18914.PubMedGoogle Scholar
  71. 71.
    Public Health Agency of Canada. Canadian National Report on Immunization, 2006. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/32s3/4epi-eng.php
  72. 72.
    Gay N, Miller E, Hesketh L, Morgan-Capner P, Ramsay M, Cohen B et al. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Commun Dis Rep CDR Rev. 1997;7(2):R21–R26.PubMedGoogle Scholar
  73. 73.
    Anderson RM, Crombie JA, Grenfell BT. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect. 1987;99(1):65–84.CrossRefPubMedGoogle Scholar
  74. 74.
    Colville A, Pugh S, Miller E. Withdrawal of a mumps vaccine. Eur J Pediatr. 1994;153(6):467–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Centers for Disease Control and Prevention. Mumps epidemic–United kingdom, 2004–2005. MMWR Morb Mortal Wkly Rep. 2006;55(7):173–5.Google Scholar
  76. 76.
    Savage E, Ramsay M, White J, Beard S, Lawson H, Hunjan R et al. Mumps outbreaks across England and Wales in 2004: observational study. BMJ. 2005;330(7500):1119–20.CrossRefPubMedGoogle Scholar
  77. 77.
    MacDonald N, Flegel K. Mumps in young adults: the canary in the coal mine. CMAJ. 2007;177(2):121, 3.Google Scholar
  78. 78.
    Wright JA, Polack C. Understanding variation in measles-mumps-rubella immunization coverage–a population-based study. Eur J Public Health. 2006;16(2):137–42.CrossRefPubMedGoogle Scholar
  79. 79.
    Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N et al. . Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerg Infect Dis. 2007;13(1):12–17.PubMedGoogle Scholar
  80. 80.
    Gabutti G, Guido M, Rota MC, De Donno A, Ciofi Degli Atti ML, Crovari P. The epidemiology of mumps in Italy. Vaccine. 2008;26(23):2906–11.CrossRefPubMedGoogle Scholar
  81. 81.
    Public Health Agency of Canada. Mumps in Canada, 2007. 2009. http://www.phac-aspc.gc.ca/mumps-oreillons/prof-eng.php
  82. 82.
    Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet. 1999;354(9187):1355–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect. 2005;51(4):294–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Richard JL, Zwahlen M, Feuz M, Matter HC. Comparison of the effectiveness of two mumps vaccines during an outbreak in Switzerland in 1999 and 2000: a case-cohort study. Eur J Epidemiol. 2003;18(6):569–77.CrossRefPubMedGoogle Scholar
  85. 85.
    Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46(8):1172–80.CrossRefPubMedGoogle Scholar
  86. 86.
    Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198(4):508–15.CrossRefPubMedGoogle Scholar
  87. 87.
    Narita M, Matsuzono Y, Takekoshi Y, Yamada S, Itakura O, Kubota M et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol. 1998;5(6):799–803.PubMedGoogle Scholar
  88. 88.
    Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA. 2000;284(20):2643–7.CrossRefPubMedGoogle Scholar
  89. 89.
    Centers for Disease Control and Prevention. Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep. 2008;57(40):1103–5.Google Scholar
  90. 90.
    Marienau KJ, Averhoff F, Redd S. The role of air travel in the spread of mumps. Clin Infect Dis. 2008;47(9):1237.CrossRefPubMedGoogle Scholar
  91. 91.
    Centers for Disease Control and Prevention. Vaccines & Immunizations. Programs & Tools. CDC Vaccine Price List. 2009. http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm
  92. 92.
    Kamerow D. Yankee doodling: jabbering about jabs. BMJ. 2008;337:a1517.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Noni MacDonald
    • 1
    • 2
  • Todd Hatchette
    • 3
  • Lotfia Elkout
    • 4
    • 5
  • Shelly Sarwal
    • 6
  1. 1.Pediatrics and Computer ScienceDalhousie UniversityHalifaxCanada
  2. 2.Division of Pediatric Infectious DiseasesIWK Health CenterHalifaxCanada
  3. 3.Division of Microbiology, Department of Pathology and Laboratory MedicineCDHA and Dalhousie UniversityHalifaxCanada
  4. 4.Pediatric Infectious DiseasesDalhousie UniversityHalifaxCanada
  5. 5.Division of Pediatric Infectious DiseasesIWK Health CenterHalifaxCanada
  6. 6.Pictou County District Health Authorities, Colchester Regional HospitalTruroCanada

Personalised recommendations